GlassScriptPhysician profile
Stacey O Lynch
NPI 1750705513
$6,276.14
in general payments reported to CMS, 2019-2025
20 companies · $396 in 2025
The $396 reported for 2025 was more than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,011 · 2022: $1,167 · 2023: $2,767 · 2024: $935 · 2025: $396.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,802 · Travel and Lodging: $1,296.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,801.56 |
| Travel and Lodging | $1,296.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,899.88 | 2021-2025 | Spravato |
| Neurocrine Biosciences, INC. | $742.87 | 2021-2025 | Ingrezza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $708.28 | 2021-2025 | Caplyta |
| Abbvie INC. | $654.77 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $524.47 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Sunovion Pharmaceuticals INC. | $522.69 | 2021-2022 | |
| Lundbeck LLC | $210.18 | 2022-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Axsome Therapeutics, INC. | $158.42 | 2023-2025 | Auvelity |
| Supernus Pharmaceuticals, INC. | $157.27 | 2021-2023 | Qelbree |
| Takeda Pharmaceuticals U.S.A., INC. | $154.00 | 2021-2024 | Trintellix |
| Alkermes, INC. | $139.49 | 2022-2025 | Aristada, Lybalvi |
| Tris Pharma INC | $104.98 | 2023-2025 | Dyanavel Xr |
| Idorsia Pharmaceuticals US INC | $83.20 | 2022-2023 | Quviviq |
| Corium, LLC | $50.64 | 2023 | Azstarys |
| Ironshore Pharmaceuticals INC. | $49.44 | 2021-2023 | Jornay Pm |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch Health US, LLC | $35.22 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $29.83 | 2022 | |
| Acadia Pharmaceuticals INC | $18.86 | 2025 | Nuplazid |
| Biogen, INC. | $18.07 | 2024 | |
| Merck Sharp & Dohme LLC | $13.58 | 2023 | Belsomra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stacey Lynch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.